RenovoRx shareholders approve equity issuance proposal allowing >20% share dilution at up to 10% discount

RenovoRx, Inc.

On Dec 15, 2023, shareholders approved Equity Issuance Proposal with 4,747,833 for, 336,779 against, 3,200 abstain.
Proposal allows issuance of shares or convertible securities exceeding 20% of outstanding common stock.
Issuance at a discount up to 10% below market price, in non-public offerings.
Quorum of 47.58% (5,087,812 shares) present.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

RenovoRx, Inc. shareholders approved Approval of issuance of shares of Common Stock in non-public offerings (Equity Issuance Proposal) at the 2023-12-15 meeting.

Outcome: passed
Meeting: 2023-12-15

Exact text from the filing

The following is a tabulation of the votes with respect to the Equity Issuance Proposal, which was approved by the Company’s stockholders: For Against Abstain 4,747,833 336,779 3,200

View on SEC.gov

Browse all shareholder votes →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-045272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.